Neurocrine Biosciences (NBIX) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Neurocrine Bio. (NBIX) PT Raised to $138 at Stifel; Nice Ingrezza Beat and Better TRx Commentary
August 3, 2021 5:54 PM EDTStifel analyst Paul Matteis raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $138.00 (from $136.00) while maintaining a Buy rating following results.
The analyst commented, "We are reiterating our Buy rating on NBIX on the back of a solid 2Q for... More



